In this installment of the “How I treat …” series in Blood, the authors present a concise practical review of vaccination guidelines for HCT recipients. They present 20 frequently asked questions (FAQs) to illustrate how to apply vaccination guidelines developed by the American Society for Blood and Marrow Transplantation (ASBMT), the European Society for Blood and Marrow Transplantation (EBMT), and the Infectious Disease Society of America (IDSA). The FAQs explain when adjustments should be made for different post-transplant clinical scenarios based on patient age, underlying diagnosis, or amount of immunosuppressive therapy.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: HCT Vaccination Guidelines
Apr 2016